File Download
Supplementary

Conference Paper: A randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results

TitleA randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results
Authors
Issue Date2013
PublisherInternational Liver Cancer Association.
Citation
A randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results. In Final program & book of abstracts: the 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013, p. 16 How to Cite?
DescriptionThe 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013
Oral Communications, Saturday 14 September, 2013, 0-022
Persistent Identifierhttp://hdl.handle.net/10722/195840

 

DC FieldValueLanguage
dc.contributor.authorKudo, M-
dc.contributor.authorFinn, R-
dc.contributor.authorPoon, RTP-
dc.contributor.authorBlanc, JF-
dc.contributor.authorHan, G-
dc.contributor.authorYan, L-
dc.contributor.authorYang, J-
dc.contributor.authorLu, L-
dc.contributor.authorTak, WY-
dc.contributor.authorXU, X-
dc.contributor.authorLee, JH-
dc.contributor.authorLin, SM-
dc.contributor.authorWu, C-
dc.contributor.authorTanwandee, T-
dc.contributor.authorShao, G-
dc.contributor.authorWalters, L-
dc.contributor.authorDela Cruz, C-
dc.contributor.authorPoulart, V-
dc.contributor.authorWang, JH-
dc.date.accessioned2014-03-14T03:01:45Z-
dc.date.available2014-03-14T03:01:45Z-
dc.date.issued2013-
dc.identifier.citationA randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial results. In Final program & book of abstracts: the 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013, p. 16-
dc.identifier.urihttp://hdl.handle.net/10722/195840-
dc.descriptionThe 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013-
dc.descriptionOral Communications, Saturday 14 September, 2013, 0-022-
dc.languageeng-
dc.publisherInternational Liver Cancer Association.-
dc.relation.ispartofFinal program & book of abstracts: the 7th Annual Conference of the International Liver Cancer Association (ILCA), Washington, D.C., USA, 13-15 September, 2013-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleA randomized, double-blind, multicenter phase 3 study of brivanib versus placebo as adjuvant therapy to trans-arterial chemoembolization in patients with unresectable hepatocellular carcinoma: initial resultsen_US
dc.typeConference_Paperen_US
dc.identifier.emailPoon, RTP: poontp@hku.hk-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros700001469-
dc.identifier.spage16-
dc.identifier.epage16-
dc.identifier.epage16-
dc.publisher.placeUnited States-
dc.customcontrol.immutableyiu 140314-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats